MiniMed Group Inc (NASDAQ:MMED) Given Consensus Rating of “Moderate Buy” by Brokerages

MiniMed Group Inc (NASDAQ:MMED) has been given an average rating of “Moderate Buy” by the fifteen analysts that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and twelve have issued a buy rating on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $21.3333.

A number of brokerages have recently issued reports on MMED. Citigroup began coverage on MiniMed Group in a research report on Tuesday, March 31st. They set a “buy” rating and a $23.00 price target on the stock. Zacks Research upgraded MiniMed Group to a “hold” rating in a report on Thursday, April 9th. Mizuho began coverage on MiniMed Group in a research note on Tuesday, March 31st. They issued an “outperform” rating and a $21.00 price target for the company. Benchmark reiterated a “buy” rating on shares of MiniMed Group in a research note on Thursday, June 4th. Finally, Barclays began coverage on MiniMed Group in a research note on Wednesday, April 1st. They issued an “overweight” rating and a $26.00 price target for the company.

MiniMed Group Stock Performance

Shares of MMED stock opened at $15.16 on Friday. MiniMed Group has a 1-year low of $10.65 and a 1-year high of $20.48. The company’s 50-day moving average is $12.91.

MiniMed Group (NASDAQ:MMED) last issued its quarterly earnings data on Wednesday, June 3rd. The company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.46). The company had revenue of $837.00 million during the quarter. The business’s quarterly revenue was up 15.6% compared to the same quarter last year.

MiniMed Group Company Profile

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.